EAM Investors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

EAM Investors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-33,456	Closed	-$1.81M	–	378
2017 Q3	$1.81M	Sell	33,456 -30,905	-48%	-$1.81M	0.24%	210
2017 Q2	$3.62M	Buy	+64,361	New	+$2.58M	0.6%	39
2016 Q1	–	Sell	-58,832	Closed	-$3.03M	–	373
2015 Q4	$3.03M	Buy	58,832 +12,605	+27%	+$611K	0.4%	113
2015 Q3	$1.97M	Buy	+46,227	New	+$2.23M	0.31%	149

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

EAM Investors's PTLA Position: Q4 2017 in Review

EAM Investors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 33,456 shares — an estimated $1.81M sold.

EAM Investors first reported a position in PTLA in Q3 2015 and held it in 4 quarters. The position peaked at $3.62M in Q2 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

EAM Investors reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
EAM Investors sold 33,456 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1.81M.
EAM Investors first reported a position in Portola Pharmaceuticals, Inc. in Q3 2015 and held it in 4 quarters.
EAM Investors's Portola Pharmaceuticals, Inc. position peaked at $3.62M in Q2 2017.
215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on EAM Investors's 13F filing for Q4 2017, filed 12 Feb 2018.